10 results about "Pattern recognition receptor" patented technology

The present invention relates to an immunogenic construct with the capability to activate the mammalian immune system. In particular, the present invention relates to an immunogenic construct comprising bacterial proteins or fragments thereof that can both target and activate immune cells through interaction with pattern recognition receptors (PRR) expressed on the immune cells.

Disclosed are compounds and compositions for inhibiting the expression of a pattern recognition receptor (e.g., STING), and methods of use thereof.

The application belongs to the field of tea polysaccharide research, and discloses a Zijuan tea polysaccharide ZTPW with immunoregulatory activity, and a preparation method and application thereof. The ZTPW is a uniform polysaccharide obtained by hot water extraction and alcohol precipitation of Zijuan tea leaves, and separation and purification through an ion exchange column and a gel column, the main repeating unit structure of which is shown in the following, and the weight average molecular weight thereof is 7.73 kDa. Through in vitro immunoregulatory activity research, the ZTPW can be recognized by pattern recognition receptors TLR2 and TLR4 to activate macrophages, significantly enhance the activity of mouse monocyte macrophage RAW264.7 cells, and mediate the production of NO and cytokines of mouse monocyte macrophage RAW264.7 through MAPKs and NF-kappa B signal pathway, so as to play an immunoregulatory role. The polysaccharide can be used as a potential immunoregulator for the development of functional food or medicine.

Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor.

The present disclosure relates, according to some embodiments, to compositions, methods, kits, and systems for detecting double-stranded RNA that include, for example, contacting a pattern recognition receptor (e.g., an oligoadenylate synthase 1; an Av cGAS-like receptor) with an RNA comprising or potentially comprising double-stranded RNA to conditionally produce (e.g., if dsRNA is present) pyrophosphate and, optionally, an oligonucleotide.

The invention belongs to the technical field of gene engineering, and relates to application of an apple pattern recognition receptor gene MdRE02 in regulation and control of plant disease resistance. The nucleotide sequence of the apple pattern recognition receptor gene MdRE02 is as shown in SEQ ID NO.1, the MdRE02 gene is silenced in apples, the expression of an immune gene induced by a pathogen-related molecular pattern VmE02 is remarkably reduced, and the disease resistance to valsa mali of apple trees is remarkably weakened. Through overexpression of the MdRE02 gene in the tobacco mutant re02, cell necrosis and active oxygen bursting induced by the VmE02 can be recovered, which indicates that the MdRE02 is a pattern recognition receptor for recognizing the VmE02. By overexpressing the MdRE02 gene in tobacco mutants re02 and oilseed rape, the resistance of the MdRE02 gene to sclerotinia sclerotiorum can be remarkably improved. The results show that the MdRE02 gene can be used for disease-resistant breeding and disease prevention and control of valsa ceratosperma and sclerotinia sclerotiorum of apple trees.

Disclosed are pharmaceutical compositions formulated from immunomodulators formed from glycogen nanoparticles, such as monodisperse phytoglycogen nanoparticles, complexed with a pattern recognition receptor agonist, such as a TLR agonist which can be poly I:C. Also disclosed are methods of treating solid tumor cancers using the described immunomodulators, and uses of the immunomodulators to treat solid tumor cancers and to manufacture medicaments to treat solid tumor cancers.

The invention discloses preparation and application of a novel immune agonist, and relates to the technical field of biological medicine, the novel immune agonist is applied to an immune response enhancement process in tumor immunotherapy, chronic virus infection treatment and vaccine adjuvant development, namely, a TLR9 mode recognition receptor on the surface of an immune cell is activated, and the immune response is enhanced. The anti-tumor or anti-infection immune response of the body is enhanced. According to the preparation and the application of the novel immune agonist, through chemical modification, targeted modification treatment is fully performed on sites possibly acted by enzyme, so that the resistance of a nucleic acid TLR9 agonist to nuclease is enhanced, the nucleic acid TLR9 agonist is not easy to degrade, a long-acting preparation technology is introduced, the circulation time of a drug in a body is prolonged through PEG modification, and the novel immune agonist can be used for preparing a novel immune agonist. The chance of enzyme degradation is further reduced, the stability and half-life period of the nucleic acid TLR9 agonist in vivo are remarkably improved, and a more lasting and effective anti-tumor or anti-infection immune response enhancement effect is achieved.

The invention belongs to the technical field of plant genetic engineering, and relates to application of an arabidopsis thaliana-derived pattern recognition receptor AtRLP30 gene in improving the fungal disease resistance of plants. The nucleotide sequence of the AtRLP30 gene is as shown in SEQ ID NO. 1. By constructing a plant expression vector containing AtRLP30 and performing overexpression in the plant, the resistance of the plant to fungal pathogen infection can be remarkably improved. Preferably, the fungi comprise ascospora poplar and ascopolyspora poplar, and the fungi comprise ascospora poplar. Experimental results show that after the AtRLP30 is overexpressed in the poplar, the transgenic plant shows stronger active oxygen accumulation, MAPK signal activation and defense related gene expression after being infected by pathogenic bacteria, and the biomass and scab area of the pathogenic bacteria are remarkably reduced. The invention proves that the AtRLP30 has the function of enhancing the fungal disease resistance in the woody plant, and provides a new gene resource and technical approach for improving the forest disease resistance by utilizing a pattern recognition receptor.

The purpose of the present invention is to provide a medicine useful for treating HIV infection by using compounds having different mechanisms in combination with kick and kill therapy. A medicine characterized by being a combination of (A) a polynucleotide or polypeptide that induces an anti-HIV Tat antibody that inhibits the activity of HIV Tat protein secreted from HIV-infected cells, and (B) a pattern recognition receptor agonist that induces type I IFN, is useful for the treatment, etc., of HIV infection.